9 results on '"Chen, Dexiang"'
Search Results
2. Epidermal powder immunization against influenza
- Author
-
Dean, Hansi J. and Chen, Dexiang
- Subjects
- *
INFLUENZA , *COMMUNICABLE diseases , *PREVENTIVE medicine , *INFLUENZA vaccines - Abstract
Abstract: Epidermal powder immunization (EPI) can efficiently deliver powdered protein vaccines to the epidermis. A phase I clinical trial was conducted to evaluate powdered trivalent influenza vaccine delivered using the PowderJect ND5.2 delivery system. Subjects received either Fluvirin® IM injection (15μg of each influenza strain), a single EPI vaccination (15μg of each influenza strain) or two adjacent EPI (total of 30μg of each influenza strain). Systemic reactogenicity was similar between control and EPI vaccines. Site reactions following EPI were primarily mild and self-limiting. Seroconversions, titer increases and geometric mean titers to all strains were equivalent or higher in EPI-immunized groups than in controls. Powdered influenza vaccine delivered by EPI is safe and elicits humoral immune responses in humans. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
3. Pre-clinical and clinical studies of epidermal powder immunization with an influenza vaccine
- Author
-
Chen, Dexiang, Dean, Hansi, and Payne, Lendon G.
- Subjects
- *
INFLUENZA vaccines , *IMMUNE response , *IMMUNIZATION , *RESPIRATORY infections - Abstract
Antigen presentation is a critical step for the immune system to mount an antigen-specific immune response to invading pathogens. Delivering antigens directly to antigen presenting cells (APCs) is a promising way to improve the immunogenicity and effectiveness of vaccines. Epidermal powder immunization (EPI) delivers vaccine to the epidermis, the superficial layer of skin containing a large number of APCs, and has been shown to elicit augmented antibody responses and cellular immunity to the split influenza vaccine in small animals, nonhuman primates, and humans. EPI is safe and effective and holds promise for future human immunization with influenza and other vaccines. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
4. Epidermal powder immunization of mice and monkeys with an influenza vaccine
- Author
-
Chen, Dexiang, Endres, Ryan, Maa, Yuh-Fun, Kensil, Charlotte R., Whitaker-Dowling, Patricia, Trichel, Anita, Youngner, Julius S., and Payne, Lendon G.
- Subjects
- *
VACCINES , *INFLUENZA - Abstract
Epidermal powder immunization (EPI) with an influenza vaccine and an adjuvant such as QS-21, LTR72, or cholera toxin elicited augmented serum and mucosal antibody responses in mice. Rhesus macaques, which have an immune system and skin structure similar to humans, were used to further evaluate the immunogenicity of the influenza vaccine following EPI. EPI of rhesus macaques with an influenza vaccine and QS-21 adjuvant elicited significantly higher serum hemagglutination inhibition (HI) titers than antigen alone administered by EPI or by intramuscular (IM) injection using a needle and syringe. In the absence of QS-21, EPI and IM injection elicited comparable HI titers in the monkeys. This study suggests that EPI is a promising technique for administering human vaccine and that QS-21 augments the immunogenicity of co-administered influenza vaccine. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
5. Immune responses to hepatitis B surface antigen following epidermal powder immunization.
- Author
-
Osorio, Jorge E, Zuleger, Cindy L, Burger, Melissa, Chu, Qili, Payne, Lendon G, and Chen, Dexiang
- Subjects
IMMUNIZATION ,HEPATITIS B ,LANGERHANS cells - Abstract
Summary Langerhans cells in the epidermis of skin are potent antigen-presenting cells that trigger the immune system to respond to invading microorganisms. We have previously shown that epidermal powder immunization with a powdered inactivated influenza virus vaccine, by targeting the Langerhans cell-rich epidermis, was more efficacious than deeper tissue injection using a needle and syringe. We now report enhanced humoral and cellular immune responses to recombinant hepatitis B surface antigen following epidermal powder immunization. We observed that epidermal powder immunization with unadjuvanted hepatitis B surface antigen elicited an antibody titre equivalent to that induced by the alum-adjuvanted vaccine delivered by intramuscular injection, suggesting that epidermal powder immunization can overcome the need for adjuvantation. We demonstrated that synthetic CpG oligonucleotides (CpG DNA) could be coformulated with hepatitis B surface antigen and delivered by epidermal powder immunization to further augment the antibody response and modulate T helper cell activities. Epidermal powder immunization of hepatitis B surface antigen formulated with CpG DNA formulations resulted in 1.5-2.0 logs higher IgG antibody titres than alum-adjuvanted commercial vaccines administered by intramuscular injection. Formulation of hepatitis B surface antigen with CpG DNA elicited an augmented IgG2a antibody response and increased frequency of IFN-γ secreting cells. In addition, CpG DNA was found to activate epidermal Langerhans cells and stimulate the production of TNF-α and IL-12 cytokines by epidermal cells, explaining its strong adjuvant activity following epidermal powder immunization. These results show that epidermal powder immunization is a safe and effective method to deliver hepatitis B surface antigen and the addition of new adjuvants, such as CpG DNA, may further enhance the efficacy of this vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
6. Vaccine stabilization: Research, commercialization, and potential impact
- Author
-
Kristensen, Debra, Chen, Dexiang, and Cummings, Ray
- Subjects
- *
VIRAL vaccines , *HIGH temperatures , *STABILITY (Mechanics) , *DRUG development , *INDUSTRIAL costs , *FROZEN drugs , *DRUG efficacy - Abstract
Abstract: All vaccines are susceptible to damage by elevated temperatures and many are also damaged by freezing. The distribution, storage, and use of vaccines therefore present challenges that could be reduced by enhanced thermostability, with resulting improvements in vaccine effectiveness. Formulation and processing technologies exist that can improve the stability of vaccines at temperature extremes, however, customization is required for individual vaccines and results are variable. Considerations affecting decisions about stabilization approaches include development cost, manufacturing cost, and the ease of use of the final product. Public sector agencies can incentivize vaccine developers to prioritize stabilization efforts through advocacy and by implementing policies that increase demand for thermostable vaccines. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
7. Strategies to advance vaccine technologies for resource-poor settings
- Author
-
Kristensen, Debra and Chen, Dexiang
- Subjects
- *
VACCINES industry , *IMMUNIZATION , *MIDDLE-income countries , *RESEARCH & development , *ORAL poliomyelitis vaccines , *MEDICAL care costs - Abstract
Abstract: New vaccine platform and delivery technologies that can have significant positive impacts on the effectiveness, acceptability, and safety of immunizations in developing countries are increasingly available. Although donor support for vaccine technology development is strong, the uptake of proven technologies by the vaccine industry and demand for them by purchasers continues to lag. This article explains the challenges and opportunities associated with accelerating the availability of innovative and beneficial vaccine technologies to meet critical needs in resource-poor settings over the next decade. Progress will require increased dialog between the public and private sectors around vaccine product attributes; establishment of specifications for vaccines that mirror programmatic needs; stronger encouragement of vaccine developers to consider novel technologies early in the product development process; broader facilitation of research and access to technologies through the formation of centers of excellence; the basing of vaccine purchase decisions on immunization systems costs rather than price per dose alone; possible subsidization of early technology adoption costs for vaccine producers that take on the risks of new technologies of importance to the public sector; and the provision of data to purchasers, better enabling them to make informed decisions that take into account the value of specific product attributes. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
8. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants
- Author
-
Braun, LaToya Jones, Tyagi, Anil, Perkins, Shalimar, Carpenter, John, Sylvester, David, Guy, Mark, Kristensen, Debra, and Chen, Dexiang
- Subjects
- *
VACCINE research , *TEMPERATURE control for drug storage , *IMMUNOLOGICAL adjuvants , *PREVENTIVE medicine , *DRUG preservation , *ALUMINUM compounds , *HEPATITIS B , *METHOXYPROPANOL , *HEPATITIS , *THERAPEUTICS - Abstract
Abstract: Vaccines containing aluminum salt adjuvants are prone to inactivation following exposure to freeze–thaw stress. Many are also prone to inactivation by heat. Thus, for maximum potency, these vaccines must be maintained at temperatures between 2°C and 8°C which requires the use of the cold chain. Nevertheless, the cold chain is not infallible. Vaccines are subject to freezing during both transport and storage, and frozen vaccines are discarded (under the best circumstances) or inadvertently administered despite potentially reduced potency. Here we describe an approach to minimize our reliance on the proper implementation of the cold chain to protect vaccines from freeze–thaw inactivation. By including PEG 300, propylene glycol, or glycerol in a hepatitis B vaccine, particle agglomeration, changes in the fluorescence emission spectrum – indicative of antigen tertiary structural changes – and losses of in vitro and in vivo indicators of potency were prevented following multiple exposures to −20°C. The effect of propylene glycol was examined in more detail and revealed that even at concentrations too low to prevent freezing at −10°C, −20°C, and −80°C, damage to the vaccine could be prevented. A pilot study using two commercially available diphtheria, tetanus toxoid, and acellular pertussis (DTaP) vaccines suggested that the same stabilizers might protect these vaccines from freeze–thaw agglomeration as well. It remains to be determined if preventing agglomeration of DTaP vaccines preserves their antigenic activity following freeze–thaw events. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
9. A protective effect of epidermal powder immunization in a mouse model of equine herpesvirus-1 infection
- Author
-
Kondo, Takashi, McGregor, Martha, Chu, Qili, Chen, Dexiang, Horimoto, Taisuke, and Kawaoka, Yoshihiro
- Subjects
- *
IMMUNIZATION , *HERPESVIRUS diseases , *VACCINES - Abstract
To evaluate the protective effect of epidermal powder immunization (EPI) against equine herpesvirus-1 (EHV-1) infection, we prepared a powder vaccine in which formalin-inactivated virions were embedded in water-soluble, sugar-based particles. A PowderJect device was used to immunize mice with the powder vaccine via their abdominal skin. We found that twice-immunized mice were protected against challenge with the wild-type virus. This protective effect was equivalent to or better than that observed in mice immunized with other types of vaccines, including a gene gun-mediated DNA vaccine containing the glycoprotein D (gD) gene or conventional inactivated virus vaccines introduced via intramuscular or intranasal injections. These findings indicate that the powder vaccine is a promising approach for the immunological control of EHV-1 infection, either alone or as a part of prime-boost vaccination strategies. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.